Recent advancements in traditional Chinese medicine for COVID-19 with comorbidities across various systems: a scoping review.

Recent advancements in traditional Chinese medicine for COVID-19 with comorbidities across various systems: a scoping review.

Publication date: Dec 19, 2024

Traditional Chinese medicine (TCM) has developed a rich theoretical system and practical experience in fighting to infectious diseases over the past thousands of years, and has played an important role in controlling the spread owing to its unique advantages. In particular, its significant contribution to the prevention and control of Corona Virus Disease 2019 (COVID-19) is widely recognized. COVID-19 infection is mainly non-severe with a favorable overall outcome, but patients with comorbidities tend to have a poor prognosis. However, a comprehensive review of TCM for preventing and treating COVID-19 with comorbidities across various systems is still lacking. Hence, this scoping review aims to conduct a comprehensive investigation on treatment outcome of TCM for treating COVID-19 with comorbidities across various systems. The scoping review was conducted by searching English databases including PubMed and Web of Science, and Chinese databases including China National Knowledge Infrastructure and Wanfang between January 2020 and January 2024. We followed the inclusion and exclusion criteria to identify relevant literature. Information for inclusion in the literature were subsequently extracted and consolidated. We enrolled 13 literature that met the inclusion criteria in the review finally. Our analysis revealed that research on COVID-19 with comorbidities was mostly focused on circulatory diseases, including hypertension, heart failure, and cerebrovascular diseases, most common comorbidities were hypertension. Followed by endocrine and metabolic diseases such as diabetes, respiratory diseases including pulmonary tuberculosis and chronic obstructive pulmonary disease have been also addressed. However, there were few studies on co-infectious urogenital system disease, and no studies on the rheumatic, immune, hematological, nervous, reproductive, and skin systems diseases. Based on existing studies, TCM has significantly improved the clinical symptoms of COVID-19 with comorbidities such as fever, fatigue, dry cough, anorexia and asthma, the absorption of lung lesions, shortened the duration of viral shedding and the course of disease. TCM has great application prospects in treating COVID-19 with comorbidities. These findings could provide important evidence for clinicians to treat COVID-19 with comorbidities. Multi-center studies are required to confirm our results in the future.

Concepts Keywords
China Clinical effect
Fighting Comorbidities
Rich Comorbidity
Tuberculosis COVID-19
Urogenital COVID-19
COVID-19 Drug Treatment
Drugs, Chinese Herbal
Drugs, Chinese Herbal
Humans
Medicine, Chinese Traditional
Review
SARS-CoV-2
Traditional Chinese medicine

Semantics

Type Source Name
disease MESH COVID-19
disease MESH infectious diseases
disease IDO role
disease MESH Virus Disease
disease MESH infection
drug DRUGBANK Methionine
disease MESH hypertension
disease MESH heart failure
disease MESH cerebrovascular diseases
disease MESH metabolic diseases
disease MESH respiratory diseases
disease MESH pulmonary tuberculosis
disease MESH chronic obstructive pulmonary disease
disease MESH anorexia
disease MESH asthma
pathway KEGG Asthma
disease MESH viral shedding
disease MESH Long Covid
disease MESH Comorbidity

Original Article

(Visited 1 times, 1 visits today)